152 related articles for article (PubMed ID: 16018932)
21. The evaluation of analgesic effects of milnacipran and sertraline in tail-flick test.
Kesim M; Yanik MN; Kadioglu M; Pepeoglu D; Erkoseoglu I; Kalyoncu NI; Yaris E
Bratisl Lek Listy; 2014; 115(1):3-6. PubMed ID: 24471894
[TBL] [Abstract][Full Text] [Related]
22. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
Morishita S; Arita S
Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
[No Abstract] [Full Text] [Related]
23. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome.
Häuser W; Urrútia G; Tort S; Uçeyler N; Walitt B
Cochrane Database Syst Rev; 2013 Jan; (1):CD010292. PubMed ID: 23440848
[TBL] [Abstract][Full Text] [Related]
24. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode.
Tignol J; Pujol-Domenech J; Chartres JP; Léger JM; Plétan Y; Tonelli I; Tournoux A; Pezous N
Acta Psychiatr Scand; 1998 Feb; 97(2):157-65. PubMed ID: 9517912
[TBL] [Abstract][Full Text] [Related]
25. Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium.
Bernstein CD; Albrecht KL; Marcus DA
Expert Opin Pharmacother; 2013 May; 14(7):905-16. PubMed ID: 23506481
[TBL] [Abstract][Full Text] [Related]
26. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients.
Yoshimura R; Mitoma M; Sugita A; Hori H; Okamoto T; Umene W; Ueda N; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1034-7. PubMed ID: 17459550
[TBL] [Abstract][Full Text] [Related]
27. Addition of a dopamine agonist, cabergoline, to a serotonin-noradrenalin reuptake inhibitor, milnacipran as a therapeutic option in the treatment of refractory depression: two case reports.
Takahashi H; Yoshida K; Higuchi H; Shimizu T; Inoue T; Koyama T
Clin Neuropharmacol; 2003; 26(5):230-2. PubMed ID: 14520161
[TBL] [Abstract][Full Text] [Related]
28. Japanese experience with dual-action antidepressants.
Tajima O
Int Clin Psychopharmacol; 2002 Jun; 17 Suppl 1():S37-42. PubMed ID: 12369609
[TBL] [Abstract][Full Text] [Related]
29. [Antidepressants with different action mechanisms in the treatment of chronic daily headache].
Amelin AV; Tarasova SV; Ignatov IuD; Skoromets AA; Miatleva MI
Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(9):38-44. PubMed ID: 18379461
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of milnacipran in patients with fibromyalgia.
Gendreau RM; Thorn MD; Gendreau JF; Kranzler JD; Ribeiro S; Gracely RH; Williams DA; Mease PJ; McLean SA; Clauw DJ
J Rheumatol; 2005 Oct; 32(10):1975-85. PubMed ID: 16206355
[TBL] [Abstract][Full Text] [Related]
31. ACS chemical neuroscience molecule spotlight on savella.
Hopkins CR
ACS Chem Neurosci; 2010 May; 1(5):345. PubMed ID: 22778830
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic effects of milnacipran (serotonin noradrenalin reuptake inhibitor) on depression following mild and moderate traumatic brain injury.
Kanetani K; Kimura M; Endo S
J Nippon Med Sch; 2003 Aug; 70(4):313-20. PubMed ID: 12928711
[TBL] [Abstract][Full Text] [Related]
33. Milnacipran for chronic pain in the orofacial region.
Pae CU
Clin Neuropharmacol; 2010; 33(5):270. PubMed ID: 20864840
[No Abstract] [Full Text] [Related]
34. Milnacipran plasma levels and antidepressant response in Japanese major depressive patients.
Higuchi H; Yoshida K; Takahashi H; Naito S; Kamata M; Ito K; Sato K; Tsukamoto K; Shimizu T; Nakanishi M; Hishikawa Y
Hum Psychopharmacol; 2003 Jun; 18(4):255-9. PubMed ID: 12766929
[TBL] [Abstract][Full Text] [Related]
35. Pharmacology and pharmacokinetics of milnacipran.
Puozzo C; Panconi E; Deprez D
Int Clin Psychopharmacol; 2002 Jun; 17 Suppl 1():S25-35. PubMed ID: 12369608
[TBL] [Abstract][Full Text] [Related]
36. [Serotonin-noradrenaline reuptake inhibitors(SNRIs)].
Ishigooka J
Nihon Rinsho; 2001 Aug; 59(8):1523-9. PubMed ID: 11519152
[TBL] [Abstract][Full Text] [Related]
37. Current progress in the pharmacological therapy of fibromyalgia.
Rao SG
Expert Opin Investig Drugs; 2009 Oct; 18(10):1479-93. PubMed ID: 19732029
[TBL] [Abstract][Full Text] [Related]
38. A comparative study of milnacipran and paroxetine in outpatients with major depression.
Sechter D; Vandel P; Weiller E; Pezous N; Cabanac F; Tournoux A;
J Affect Disord; 2004 Dec; 83(2-3):233-6. PubMed ID: 15555719
[TBL] [Abstract][Full Text] [Related]
39. Milnacipran in panic disorder with agoraphobia and major depressive disorder: a case report.
Chen MH; Liou YJ
Clin Neuropharmacol; 2011; 34(5):201-2. PubMed ID: 21926486
[TBL] [Abstract][Full Text] [Related]
40. Levomilnacipran (Fetzima) a new SNRI for depression.
Med Lett Drugs Ther; 2013 Dec; 55(1432):101-2. PubMed ID: 24419243
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
